Pan-HER antibody composition
US10221246B2 · kind B2 · utility
2Cited by
9References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 28, 2016 |
| Grant date | Mar 5, 2019 |
| Priority date | — |
| Expiry date | Nov 28, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.